Approval

BlackRock, the world’s largest asset manager, is planning to slash its global workforce in the coming days, according to the latest report. This move comes while the firm expects to receive positive news from the US Securities and…

This year, the spot Bitcoin ETF approval by the US Securities and Exchange Commission (SEC) is deemed certain by just 39% of financial advisors, according to a recent survey. The survey’s findings demonstrate that financial…

In a stern warning to the US Securities and Exchange Commission (SEC), Dennis M. Kelleher, Co-Founder and CEO of Better Markets, a non-profit organization that focuses on advancing public financial interest, has issued a statement…

In a significant stride towards the potential approval of Spot Bitcoin Exchange-Traded Funds (ETFs) in the United States, applicants have overcome a pivotal hurdle, marking a crucial milestone in their quest for regulatory approval from the…

The Nasdaq has submitted an amendment for BlackRock and Valkyrie's Spot Bitcoin Exchange-Traded Fund (ETF) 19b-4 filings, inching closer to the looming approval deadline this coming Wednesday. The amendment…

Former executives of Citigroup Inc. will offer Bitcoin (BTC)-backed securities. According to a Bloomberg report published on Jan. 4 former Citigroup executives will offer BTC-backed securities that they say do not need approval from US…

The recent flash crash of Bitcoin from over $45,500 to as low as $41,100 has sent shockwaves throughout the crypto community, sparking debate over the underlying causes. While some have attributed the crash to…

The US Securities and Exchange Commission may approve a spot Bitcoin ETF, according to recent speculations that rocked the digital asset market. Due to these conjectures, Bitcoin surged to over 6% on the second day of 2024,…

The widely anticipated approval of over a dozen spot Bitcoin exchange-traded funds (ETFs) in the United States could be a sell-the-news event that would cause the price of BTC to move in the opposite direction. According to…

Bill Oxford/iStock via Getty Images Following the recent FDA green light for the gene therapy Casgevy, "it is unlikely" that approval of a similar product will take place "any time soon," according to a report by GlobalData. According…